HC Wainwright Has Positive Outlook for Nyxoah Q1 Earnings

Nyxoah S.A. (NASDAQ:NYXH) – Investment analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of Nyxoah in a report released on Wednesday, March 26th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($0.48) for the quarter, up from their previous estimate of ($0.50). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Nyxoah’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Nyxoah’s Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.86) EPS and FY2027 earnings at ($0.58) EPS.

Separately, Stifel Nicolaus cut their price target on Nyxoah from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, March 14th.

Nyxoah Stock Down 4.4 %

Shares of NYXH opened at $7.65 on Friday. The firm has a market capitalization of $260.56 million, a price-to-earnings ratio of -4.09 and a beta of 1.42. Nyxoah has a 52 week low of $6.76 and a 52 week high of $13.50. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. The business’s fifty day moving average price is $10.35 and its two-hundred day moving average price is $9.34.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. The company had revenue of $1.35 million during the quarter, compared to analyst estimates of $2.02 million.

Institutional Trading of Nyxoah

A number of institutional investors have recently bought and sold shares of NYXH. Kovack Advisors Inc. lifted its stake in shares of Nyxoah by 100.0% in the 4th quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock valued at $160,000 after purchasing an additional 10,000 shares during the period. LPL Financial LLC bought a new stake in Nyxoah in the fourth quarter valued at about $102,000. Geode Capital Management LLC lifted its stake in Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after buying an additional 2,774 shares during the period. Renaissance Technologies LLC bought a new position in Nyxoah during the fourth quarter worth about $187,000. Finally, Walleye Capital LLC grew its position in shares of Nyxoah by 23.9% during the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock worth $119,000 after buying an additional 2,862 shares during the period.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.